Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial

• Published in: JAMA network open Vol. 4; no. 10; p. e2129566
• Main Authors: Dinh, Aurélien, Duran, Clara, Ropers, Jacques, Bouchand, Frédérique, Davido, Benjamin, Deconinck, Laurène, Matt, Morgan, Senard, Olivia, Lagrange, Aurore, Mellon, Guillaume, Calin, Ruxandra, Makhloufi, Sabrina, de Lastours, Victoire, Mathieu, Emmanuel, Kahn, Jean-Emmanuel, Rouveix, Elisabeth, Grenet, Julie, Dumoulin, Jennifer, Chinet, Thierry, Pépin, Marion, Delcey, Véronique, Diamantis, Sylvain, Benhamou, Daniel, Vitrat, Virginie, Dombret, Marie-Christine, Guillemot, Didier, Renaud, Bertrand, Claessens, Yann-Erick, Labarère, José, Aegerter, Philippe, Bedos, Jean-Pierre, Crémieux, Anne-Claude
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.10.2021
• Subjects: Age; Aged; Aged, 80 and over; Antibiotics; Clinical trials; Community-Acquired Infections - epidemiology; Community-Acquired Infections - therapy; Duration of Therapy; Female; Hospitalization - statistics & numerical data; Human health and pathology; Humans; Infectious Diseases; Life Sciences; Male; Middle Aged; Online Only; Original Investigation; Pneumonia; Pneumonia - epidemiology; Pneumonia - therapy; Pulmonology and respiratory tract; Risk Factors; Santé publique et épidémiologie; Treatment Failure
• ISSN: 2574-3805; 2574-3805
• DOI: 10.1001/jamanetworkopen.2021.29566

Failure of treatment is the most serious complication in community-acquired pneumonia (CAP). To assess the potential risk factors for treatment failure in clinically stable patients with CAP. This secondary analysis assesses data from a randomized clinical trial on CAP (Pneumonia Short Treatment [PTC] trial) conducted from December 19, 2013, to February 1, 2018. Data analysis was performed from July 18, 2019, to February 15, 2020. Patients hospitalized at 1 of 16 centers in France for moderately severe CAP who were clinically stable at day 3 of antibiotic treatment were included in the PTC trial and analyzed in the per-protocol trial population. Patients were randomly assigned (1:1) on day 3 of antibiotic treatment to receive β-lactam (amoxicillin-clavulanate [1 g/125 mg] 3 times daily) or placebo for 5 extra days. The main outcome was failure at 15 days after first antibiotic intake, defined as a temperature greater than 37.9 °C and/or absence of resolution or improvement of respiratory symptoms and/or additional antibiotic treatment for any cause. The association among demographic characteristics, baseline clinical and biological variables available (ie, at the first day of β-lactam treatment), and treatment failure at day 15 among the per-protocol trial population was assessed by univariate and multivariable logistic regressions. Overall, 310 patients were included in the study; this secondary analysis comprised 291 patients (174 [59.8%] male; mean [SD] age, 69.6 [18.5] years). The failure rate was 26.8%. Male sex (odds ratio [OR], 1.74; 95% CI, 1.01-3.07), age per year (OR, 1.03; 95% CI, 1.01-1.05), Pneumonia Severe Index score (OR, 1.01; 95% CI, 1.00-1.02), the presence of chronic lung disease (OR, 1.85; 95% CI, 1.03-3.30), and creatinine clearance (OR, 0.99; 95% CI, 0.98-1.00) were significantly associated with failure in the univariate analysis. When the Pneumonia Severe Index score was excluded to avoid collinearity with age and sex in the regression model, only male sex (OR, 1.92; 95% CI, 1.08-3.49) and age (OR, 1.02; 95% CI, 1.00-1.05) were associated with failure in the multivariable analysis. In this secondary analysis of a randomized clinical trial, among patients with CAP who reached clinical stability after 3 days of antibiotic treatment, only male sex and age were associated with higher risk of failure, independent of antibiotic treatment duration and biomarker levels. Another randomized clinical trial is needed to evaluate the impact of treatment duration in populations at higher risk for treatment failure.